Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. More Details
Excellent balance sheet with solid track record and pays a dividend.
Share Price & News
How has Alembic Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: APLLTD is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: APLLTD's weekly volatility (3%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: APLLTD underperformed the Indian Pharmaceuticals industry which returned 42.5% over the past year.
Return vs Market: APLLTD underperformed the Indian Market which returned 53% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Alembic Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StDid Alembic Pharmaceuticals' (NSE:APLLTD) Share Price Deserve to Gain 85%?
1 month ago | Simply Wall StHere's Why I Think Alembic Pharmaceuticals (NSE:APLLTD) Might Deserve Your Attention Today
1 month ago | Simply Wall StAlembic Pharmaceuticals (NSE:APLLTD) Has A Pretty Healthy Balance Sheet
Is Alembic Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: APLLTD (₹946) is trading above our estimate of fair value (₹692.93)
Significantly Below Fair Value: APLLTD is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: APLLTD is good value based on its PE Ratio (15.6x) compared to the Indian Pharmaceuticals industry average (26x).
PE vs Market: APLLTD is good value based on its PE Ratio (15.6x) compared to the Indian market (23.8x).
Price to Earnings Growth Ratio
PEG Ratio: APLLTD's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: APLLTD is overvalued based on its PB Ratio (3.6x) compared to the IN Pharmaceuticals industry average (3.4x).
How is Alembic Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: APLLTD's earnings are forecast to decline over the next 3 years (-5.4% per year).
Earnings vs Market: APLLTD's earnings are forecast to decline over the next 3 years (-5.4% per year).
High Growth Earnings: APLLTD's earnings are forecast to decline over the next 3 years.
Revenue vs Market: APLLTD's revenue (8.5% per year) is forecast to grow slower than the Indian market (12.6% per year).
High Growth Revenue: APLLTD's revenue (8.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: APLLTD's Return on Equity is forecast to be low in 3 years time (16.7%).
How has Alembic Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: APLLTD has high quality earnings.
Growing Profit Margin: APLLTD's current net profit margins (21.8%) are higher than last year (18%).
Past Earnings Growth Analysis
Earnings Trend: APLLTD's earnings have grown by 18.3% per year over the past 5 years.
Accelerating Growth: APLLTD's earnings growth over the past year (42.1%) exceeds its 5-year average (18.3% per year).
Earnings vs Industry: APLLTD earnings growth over the past year (42.1%) underperformed the Pharmaceuticals industry 58.3%.
Return on Equity
High ROE: APLLTD's Return on Equity (22.6%) is considered high.
How is Alembic Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: APLLTD's short term assets (₹25.8B) exceed its short term liabilities (₹12.8B).
Long Term Liabilities: APLLTD's short term assets (₹25.8B) exceed its long term liabilities (₹3.6B).
Debt to Equity History and Analysis
Debt Level: APLLTD's debt to equity ratio (9.9%) is considered satisfactory.
Reducing Debt: APLLTD's debt to equity ratio has increased from 8.6% to 9.9% over the past 5 years.
Debt Coverage: APLLTD's debt is well covered by operating cash flow (292.8%).
Interest Coverage: APLLTD's interest payments on its debt are well covered by EBIT (89.8x coverage).
What is Alembic Pharmaceuticals's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: APLLTD's dividend (1.48%) is higher than the bottom 25% of dividend payers in the Indian market (0.36%).
High Dividend: APLLTD's dividend (1.48%) is in the top 25% of dividend payers in the Indian market (1.44%)
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, APLLTD has been paying a dividend for less than 10 years.
Growing Dividend: APLLTD's dividend payments have increased, but the company has only paid a dividend for 9 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (23%), APLLTD's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: APLLTD's dividends in 3 years are forecast to be well covered by earnings (18% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chirayu Amin (75 yo)
Mr. Chirayu Ramanbha Amin, M.B.A. (U.S.A.), has been Chief Executive Officer of Alembic Pharmaceuticals Limited since April 27, 2016. Mr. Amin served as Managing Director of Alembic Pharmaceuticals Limited...
CEO Compensation Analysis
Compensation vs Market: Chirayu's total compensation ($USD4.23M) is above average for companies of similar size in the Indian market ($USD620.84K).
Compensation vs Earnings: Chirayu's compensation has been consistent with company performance over the past year.
Experienced Management: APLLTD's management team is seasoned and experienced (5.8 years average tenure).
Experienced Board: APLLTD's board of directors are seasoned and experienced ( 10.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.3%.
Alembic Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources
- Name: Alembic Pharmaceuticals Limited
- Ticker: APLLTD
- Exchange: NSEI
- Founded: 1907
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₹185.949b
- Shares outstanding: 196.56m
- Website: https://www.alembicpharmaceuticals.com
Number of Employees
- Alembic Pharmaceuticals Limited
- Alembic Road
Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients (API) and formulations. The company als...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/23 17:08|
|End of Day Share Price||2021/07/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.